In 1964, a child’s chance of surviving the most common form of Leukemia was 3%. Today it has increased to 91%!
When a team faces multiple submissions in a short timeframe or even simultaneous submissions, uncertainty over timeline organization and the best way to utilize medical writers can be paralyzing.
With the summer in full swing, vacations and long weekends by the pool are top of mind.
Although we all have the best intentions to use our paid time off each year, it is also not a secret that Americans are truly terrible at taking time off. According to Project: Time Off, 52% of American employees reported having unused vacation days at the end of 2017.
Understanding Why Creative Solutions Are Necessary
With last month’s celebration of Rare Disease Month and specifically, Rare Disease Day, awareness of the research challenges faced by patients and pharma companies are especially high during this season.
January 10, 2018
CYCLE FOR SURVIVAL 2018
Every dollar represents hope, strength, and a lasting impact!
October 3, 2017
In pharmaceutical clinical trials, considering competing risk analyses is highly important. Competing risks are events that may occur and prevent the evaluation of a specific primary endpoint, in turn biasing risk estimations or drug efficacy.
August 15, 2017
To Improve Real-Time Visibility of Clinical Trial Documentation and Inspection-Readiness
Veristat has completed the validation and configuration of Master Control’s eTMF system, which is now implemented and available for Veristat managed clinical trials.
August 3, 2017
Last week, Veristat attended the Massachusetts Biotechnology Council (MassBio) forum titled “Evolution of an Academic Discovery: First Person Account of the Development of Velcade®”.
Veristat Participates in Cycle for Survival 2017 and Raises over $25,000 to Fund Rare Cancer Research
February 23, 2017
On Saturday, February 4, Team Veristat joined the battle against rare cancers at the 2017 Cycle for Survival event! Team Veristat had 14 riders at the Boston, MA event, including 2 colleagues from our UK office. Our team surpassed our goal of raising over $25,000 to fund rare cancer research!